Florida Senate - 2020                        COMMITTEE AMENDMENT
       Bill No. SB 1094
                              LEGISLATIVE ACTION                        
                    Senate             .             House              

       The Committee on Health Policy (Diaz) recommended the following:
    1         Senate Amendment (with title amendment)
    3         Delete lines 32 - 126
    4  and insert:
    5  purposes of this subsection, the term “other pharmaceutical
    6  services” means the monitoring of the patient’s drug therapy and
    7  assisting the patient in the management of his or her drug
    8  therapy, and includes reviewing, and making recommendations
    9  regarding, review of the patient’s drug therapy and health care
   10  status in communication with the patient’s prescribing health
   11  care provider as licensed under chapter 458, chapter 459,
   12  chapter 461, or chapter 466, or a similar statutory provision in
   13  another jurisdiction, or such provider’s agent or such other
   14  persons as specifically authorized by the patient, regarding the
   15  drug therapy. However, nothing in this subsection may not be
   16  interpreted to permit an alteration of a prescriber’s
   17  directions, the diagnosis or treatment of any disease, the
   18  initiation of any drug therapy, the practice of medicine, or the
   19  practice of osteopathic medicine, unless otherwise permitted by
   20  law. The term “practice of the profession of pharmacy” also
   21  includes any other act, service, operation, research, or
   22  transaction incidental to, or forming a part of, any of the
   23  foregoing acts, requiring, involving, or employing the science
   24  or art of any branch of the pharmaceutical profession, study, or
   25  training, and shall expressly permit a pharmacist to transmit
   26  information from persons authorized to prescribe medicinal drugs
   27  to their patients. The practice of the profession of pharmacy
   28  also includes the administration of vaccines to adults pursuant
   29  to s. 465.189 and the preparation of prepackaged drug products
   30  in facilities holding Class III institutional pharmacy permits.
   31  The term also includes ordering and evaluating any laboratory or
   32  clinical testing; conducting patient assessments; and modifying,
   33  discontinuing, or administering medicinal drugs pursuant to s.
   34  465.0125 by a consultant pharmacist.
   35         Section 2. Section 465.0125, Florida Statutes, is amended
   36  to read:
   37         465.0125 Consultant pharmacist license; application,
   38  renewal, fees; responsibilities; rules.—
   39         (1) The department shall issue or renew a consultant
   40  pharmacist license upon receipt of an initial or renewal
   41  application that which conforms to the requirements for
   42  consultant pharmacist initial licensure or renewal as adopted
   43  promulgated by the board by rule and a fee set by the board not
   44  to exceed $250. To be licensed as a consultant pharmacist, a
   45  pharmacist must complete additional training as required by the
   46  board.
   47         (a)A consultant pharmacist may provide medication
   48  management services in a health care facility within the
   49  framework of a written collaborative practice agreement between
   50  the pharmacist and a health care facility medical director or a
   51  physician licensed under chapter 458 or chapter 459, a podiatric
   52  physician licensed under chapter 461, or a dentist licensed
   53  under chapter 466 who is authorized to prescribe medicinal
   54  drugs. A consultant pharmacist may provide medication management
   55  services, conduct patient assessments, and order and evaluate
   56  laboratory or clinical testing only for patients of the health
   57  care practitioner with whom the consultant pharmacist has a
   58  written collaborative practice agreement.
   59         (b)A written collaborative practice agreement must outline
   60  the circumstances under which the consultant pharmacist may:
   61         1.Order and evaluate any laboratory or clinical tests to
   62  promote and evaluate patient health and wellness, and monitor
   63  drug therapy and treatment outcomes.
   64         2.Conduct patient assessments as appropriate to evaluate
   65  and monitor drug therapy.
   66         3.Modify or discontinue medicinal drugs as outlined in the
   67  agreed-upon patient-specific order or preapproved treatment
   68  protocol under the direction of a physician. However, a
   69  consultant pharmacist may not modify or discontinue medicinal
   70  drugs prescribed by a health care practitioner who does not have
   71  a written collaborative practice agreement with the consultant
   72  pharmacist.
   73         4.Administer medicinal drugs.
   74         (c)A The consultant pharmacist shall maintain be
   75  responsible for maintaining all drug, patient care, and quality
   76  assurance records as required by law and, with the collaborating
   77  practitioner, shall maintain written collaborative practice
   78  agreements that must be available upon request from or upon
   79  inspection by the department.
   80         (d)This subsection does not authorize a consultant
   81  pharmacist to diagnose any disease or condition.
   82         (e)For purposes of this subsection, the term “health care
   83  facility” means an ambulatory surgical center or hospital
   84  licensed under chapter 395, an alcohol or chemical dependency
   85  treatment center licensed under chapter 397, an inpatient
   86  hospice licensed under part IV of chapter 400, a nursing home
   87  licensed under part II of chapter 400, an ambulatory care center
   88  as defined in s. 408.07, or a nursing home component under
   89  chapter 400 within a continuing care facility licensed under
   90  chapter 651 for establishing drug handling procedures for the
   91  safe handling and storage of drugs. The consultant pharmacist
   92  may also be responsible for ordering and evaluating any
   93  laboratory or clinical testing when, in the judgment of the
   94  consultant pharmacist, such activity is necessary for the proper
   95  performance of the consultant pharmacist’s responsibilities.
   96  Such laboratory or clinical testing may be ordered only with
   97  regard to patients residing in a nursing home facility, and then
   98  only when authorized by the medical director of the nursing home
   99  facility. The consultant pharmacist must have completed such
  100  additional training and demonstrate such additional
  101  qualifications in the practice of institutional pharmacy as
  102  shall be required by the board in addition to licensure as a
  103  registered pharmacist.
  104         (2) Notwithstanding the provisions of subsection (1), a
  106  ================= T I T L E  A M E N D M E N T ================
  107  And the title is amended as follows:
  108         Delete line 5
  109  and insert:
  110         465.0125, F.S.; requiring a pharmacist to complete
  111         additional training to be licensed as a consultant
  112         pharmacist; authorizing a consultant pharmacist to